Germline mutations and risk for advanced prostate cancer

Many people are increasingly interested in whether genetic testing can help them to understand their risk for cancer. The basic answer is that “Yes, it can.” However, what is also clear is that it is only going to be helpful for a small percentage of the population. … READ MORE …

Prediction of potentially lethal forms of prostate cancer

An international, multi-institutional group of researchers appears to have been able to validate a new way to predict risk for aggressive forms of localized prostate cancer that have a high probability for progression to metastatic disease and prostate cancer-specific mortality. … READ MORE …

Prostate cancer and its management: where we are at now

A relatively long article in the June 21 issue of US News & World Report discusses a series of topical issues related to the diagnosis and management of prostate cancer, including: … READ MORE …

What is “Prostac” and where can you get it?

Someone asked the sitemaster yesterday about a new test for risk of prostate cancer called Prostac® and where he could access this. … READ MORE …

Are genomic tests for prognostic risk at diagnosis really helpful (yet)?

One of the critical and unanswered questions about the value of genomic/genetic testing in relation to the diagnosis and prognosis of prostate cancer is, “What are the currently available tests actually telling us compared to the clinical data?” … READ MORE …

Medicare to cover genetic/genomic testing in advanced cancers

In an important decision announced late on Friday last week, the Centers for Medicare & Medicaid Services (CMS) announced that it had agreed to cover costs associated with genetic/genomic testing for Medicare patients with many advanced forms of cancer. … READ MORE …

Genomic testing and management of low-/intermediate-risk prostate cancer

A new paper has provided us with data on the ability of genomic testing to predict adverse pathology in a man undergoing a multiparametric MRI (mpMRI) and subsequent biopsy for risk of prostate cancer. … READ MORE …

The 400,000+ CAP screening trial reports initial results

A while ago now we had first mentioned the “Cluster randomized trial of PSA testing for prostate cancer” or CAP trial — the single largest randomized trial of PSA screening for risk of prostate cancer to be implemented. … READ MORE …

Liquid biopsies, ctDNA, and the diagnosis and management of cancers

The American Society of Clinical Oncology (ASCO) and the College of Pathologists (CAP) have just issued a joint review of available information on clinical use of “liquid biopsies” to assess circulating levels of tumor DNA (ctDNA). … READ MORE …

New test now available for identification of AR-V7 mutations in mCRPC

According to a media release issued yesterday, Genomic Health has now made available a commercial test for risk of the AR-V7 mutation in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

What did you hope to learn from your genetic test … if you have ever had one?

There’s a very nice article today on the MedPage Today web site about the medical value of “at-home genetic testing” (i.e., the sorts of tests available from companies like 23&Me and some others). … READ MORE …

Commercially available liquid biopsy data may be misleading

A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market them — to have high clinical sensitivity and specificity in the identification of specific genetic markers associated with high-risk forms of prostate cancer. … READ MORE …

FDA approves key genetic/genomic test for cancer mutations

According to reports from the Associated Press and others, some time late last Thursday the  US Food & Drug Administration (FDA) appears to have approved the use of the FoundationOne CDx genetic/genomic test for patients with “advanced or widely spread cancers.” A media release from Foundation Medicine is also available on line. … READ MORE …

The role of the phi test prior to decisions about prostate biopsies

Yesterday morning, a newly published paper was brought to my attention. It reports that use of the Prostate Health Index or phi test in a partially prospective study can and did change urologists’ opinions about whether selected patients really do or don’t need to have a prostate  biopsy. … READ MORE …

Risk, genomic risk, and prognosis of risk for prostate cancer metastasis and death

A recently published study in European Urology has again (partially) validated the utility of a specific type of genomic testing as a way to project risk for progressive disease in men initially diagnosed with localized prostate cancer. … READ MORE …